Clearmind Medicine (CMND) announced another key milestone in its Phase I/IIa clinical trial for the treatment of Alcohol Use Disorder: the first participant has been enrolled and dosed with CMND-100, its proprietary MEAI-based oral drug candidate, at Hadassah-University Medical Center in Jerusalem, Israel. The trial at Hadassah-University Medical Center is led by Prof. Joseph Caraco, Director of the Clinical Pharmacology Unit in the Department of Medicine. This site is part of the Company’s multinational Phase I/IIa clinical trial evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of CMND-100 in patients with AUD. Recent top-line results from the first cohort and unanimous Data and Safety Monitoring Board recommendation that the clinical trial continue contribute to supporting strong momentum across all active sites.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Clearmind Medicine announces milestones in Phase I/IIa trial for CMND-100
- Clearmind Medicine files to sell 5.78M common shares for holders
- Clearmind kicks off patient enrollment at Tel Aviv Sourasky Medical Center
- Clearmind says DSMB approves continuation of Phase I/IIa trial of CMND-100
- Psychedelic: Clearmind reports results from first cohort in AUD trial